Core Viewpoint - The financial performance and trading activity of Shengjian Medical indicate a mixed sentiment among investors, with notable fluctuations in financing and stockholder dynamics [1][2][3]. Group 1: Financial Performance - Shengjian Medical reported a revenue of 7.897 billion yuan for the period from January to September 2025, reflecting a year-on-year growth of 30.10% [2]. - The company's net profit attributable to shareholders reached 732 million yuan, marking a year-on-year increase of 32.36% [2]. - Cumulatively, the company has distributed 2.875 billion yuan in dividends since its A-share listing, with 1.729 billion yuan paid out in the last three years [3]. Group 2: Trading Activity - On January 28, Shengjian Medical's stock price fell by 1.41%, with a trading volume of 164 million yuan [1]. - The financing buy-in amount for the day was 16.99 million yuan, while the financing repayment was 18.75 million yuan, resulting in a net financing outflow of 1.76 million yuan [1]. - As of January 28, the total balance of margin trading for Shengjian Medical was 380 million yuan, with the financing balance accounting for 1.78% of the circulating market value, indicating a high level compared to the past year [1]. Group 3: Shareholder Dynamics - As of September 30, 2025, the number of shareholders for Shengjian Medical increased to 32,100, up by 15.06% from the previous period [2]. - The average number of circulating shares per shareholder rose to 18,048 shares, an increase of 186.92% compared to the last period [2]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by Huabao Zhongzheng Medical ETF and a slight increase by Hong Kong Central Clearing Limited [3].

Group 1 - The core point of the news is that Steady Medical has experienced a decline in stock price, dropping 5.07% to 36.15 CNY per share, with a total market value of 21.051 billion CNY [1] - Steady Medical's stock has fallen for three consecutive days, with a cumulative decline of 4.15% during this period [1] - The company, established on August 24, 2000, specializes in the research, production, and sales of cotton products, with its main revenue sources including wet and dry cotton towels (19.87%), surgical consumables (18.15%), traditional wound care products (13.88%), and sanitary napkins (13.02%) [1] Group 2 - From the perspective of fund holdings, one fund under Fuan Da has Steady Medical as a top ten holding, with 12,500 shares held, representing 0.97% of the fund's net value [2] - The fund, Fuan Da Steady Allocation 6-Month Holding Period Mixed Fund (015047), has reported a year-to-date return of 0.57% and a one-year return of 7.06% [2] - The fund manager, Zhao Hengyi, has a tenure of over 14 years, with the best fund return during his management being 44.66% [2]

Core Viewpoint - The stock of Wanjian Medical has experienced fluctuations, with a recent decline of 2.03%, and the company shows a mixed performance in terms of stock price changes over different time frames [1]. Company Overview - Wanjian Medical, established on August 24, 2000, and listed on September 17, 2020, is located in Longhua District, Shenzhen, Guangdong Province. The company specializes in the research, production, and sales of cotton products [1]. - The main revenue sources for Wanjian Medical include: - Consumer products - wet and dry cotton towels (19.87%) - Medical consumables - operating room consumables (18.15%) - Medical consumables - traditional wound care and dressing products (13.88%) - Consumer products - sanitary napkins (13.02%) - Consumer products - adult apparel (12.73%) - Consumer products - infant and children's apparel and supplies (11.36%) - Other spun products (5.24%) - Other non-woven products (4.88%) - Other (supplementary) (0.87%) [1]. Financial Performance - For the period from January to September 2025, Wanjian Medical achieved a revenue of 7.897 billion yuan, reflecting a year-on-year growth of 30.10%. The net profit attributable to the parent company was 732 million yuan, with a year-on-year increase of 32.36% [2]. - Since its A-share listing, Wanjian Medical has distributed a total of 2.875 billion yuan in dividends, with 1.729 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, Wanjian Medical had 32,100 shareholders, an increase of 15.06% from the previous period. The average circulating shares per person rose to 18,048 shares, up by 186.92% [2]. - The top shareholders include: - Huabao Zhongzheng Medical ETF (512170) - 6.5935 million shares, decreased by 841,200 shares - Hong Kong Central Clearing Limited - 4.8997 million shares, increased by 823,000 shares - E Fund Growth Enterprise Board ETF (159915) - 3.8804 million shares, decreased by 656,700 shares [3].

Investment Rating - The report maintains a "Strong Buy" rating for the company with a target price of 51.4 CNY per share [2][8]. Core Insights - The company reported a revenue of 7.3 billion CNY and a net profit of 6.8 billion CNY for the first three quarters of 2025, reflecting a year-on-year growth of 30.1% and 32.4% respectively [2]. - The medical business is experiencing robust growth driven by high-value products and expansion into overseas markets, with a revenue increase of 44.4% year-on-year [8]. - The consumer goods segment also shows strong performance, with a revenue increase of 19.1% year-on-year, led by strategic product categories [8]. Financial Performance Summary - For the first three quarters of 2025, the company achieved a gross margin of 48.3%, a slight increase of 0.2 percentage points year-on-year [8]. - The company’s net profit margin for the same period was 9.3%, up by 0.2 percentage points year-on-year [8]. - The projected total revenue for 2025 is estimated at 11.3 billion CNY, with a year-on-year growth rate of 26.2% [4]. Business Segment Analysis - **Medical Business**: Revenue reached 38.3 billion CNY in the first three quarters, with significant growth in surgical consumables and high-end dressings [8]. - **Consumer Goods**: The segment generated 40.1 billion CNY in revenue, with notable growth in flagship products like sanitary napkins, which saw a 63.9% increase in sales [8]. Profitability and Cost Management - The company’s operating expenses have increased due to the integration of GRI, but overall profitability remains strong with a projected net profit of 10.0 billion CNY for 2025 [8]. - The report indicates a decrease in sales and management expense ratios, contributing to improved profitability metrics [8].

Summary of the Conference Call for稳健医疗 Company Overview - **Company**: 稳健医疗 (Steady Medical) - **Industry**: Medical Supplies and Health Consumer Products Key Points and Arguments 1. **Financial Performance**: In the first three quarters of 2025, the company reported a revenue increase of 30% year-on-year and a net profit increase of 32%, indicating a recovery growth phase post-pandemic driven by the synergy between the medical and consumer segments [2][3][31] 2. **Medical Segment Growth**: The high-end dressing business saw a revenue growth of 30% in 2024 with a gross margin exceeding 50%. The surgical consumables business, after consolidating GRI, experienced a growth rate close to 200%, becoming a key driver for the medical segment [2][3][31] 3. **Consumer Products Segment**: The health consumer products segment focuses on four core categories: wet and dry cotton towels, sanitary napkins, adult clothing, and children's clothing. The sanitary napkin business grew over 60%, making it the fastest-growing category in the consumer segment [2][3][31] 4. **Brand Strategy**: The company achieved significant success in the cotton towel and sanitary napkin markets through a "hit product" strategy, with products like ultra-soft cotton towels and medical-grade sanitary napkins seeing growth rates exceeding 300% and doubling, respectively [2][20][21] 5. **E-commerce Expansion**: The company is actively expanding its online channels, particularly in live-streaming e-commerce, which, although currently below the industry average, has significant growth potential and is expected to become a key driver for future performance [2][3][31] 6. **Mergers and Acquisitions**: Through acquisitions like GRI, the company has supplemented key categories and driven rapid growth in related businesses, enhancing its positioning as a one-stop procurement solution for consumables [2][15][31] 7. **Future Growth Projections**: The medical business is expected to maintain a growth rate of around 13% over the next two years, while the consumer products segment is projected to grow between 13% and 18%, indicating high-quality growth potential [3][31] 8. **Market Position**: In the low-value medical consumables industry, the company holds a competitive edge with a gross margin of 36.52%, higher than competitors like 澳美 and 正德 [10][31] 9. **International Market Strategy**: The company is enhancing its own brand development in international markets and expanding through cross-border e-commerce, focusing on both B2B and B2C channels [13][31] 10. **Product Structure**: The company’s main product categories include traditional wound care products, high-end dressings, surgical room consumables, disease control protection products, and health care products, with significant revenue contributions from each [14][31] Additional Important Insights 1. **Management and Ownership**: The actual controller, Mr. Li Jianxian, and his family hold nearly 70% of the shares, with a management team comprising experienced executives from both the medical and fast-moving consumer goods sectors [8][31] 2. **Market Dynamics**: The sanitary napkin market is experiencing significant changes, with traditional leading brands losing market share, providing opportunities for emerging brands like 奈斯公主 [28][29][30] 3. **Consumer Trends**: The company is focusing on enhancing brand image and values through various marketing strategies, including social media and live-streaming, to attract younger consumers [21][30] 4. **Challenges in Baby Clothing Segment**: The growth of the children's clothing segment is expected to be limited due to declining birth rates, with only single-digit growth projected for 2025 [19][23][31] This comprehensive summary captures the essential aspects of the conference call, highlighting the company's performance, strategic initiatives, and market positioning within the medical and consumer products sectors.

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company has achieved continuous high-quality growth in the first three quarters of 2025, with a revenue of 7.897 billion yuan, representing a year-on-year increase of 30.10%. The net profit attributable to the parent company reached 732 million yuan, up 32.36% year-on-year [4][6] - The medical segment reported a revenue of 3.83 billion yuan in Q1-Q3 2025, a year-on-year growth of 44.4%, driven by rapid development in core categories such as surgical consumables and high-end dressings [4][6] - The consumer segment generated a revenue of 4.01 billion yuan in Q1-Q3 2025, with a year-on-year increase of 19.1%, led by strong sales of specific products like sanitary napkins [4][6] Summary by Sections Recent Performance - In Q3 2025, the company achieved a revenue of 2.601 billion yuan, a year-on-year increase of 27.71%, and a net profit of 240 million yuan, up 42.11% year-on-year [4] - The company’s stock performance over the past year shows a 30.4% increase, outperforming the CSI 300 index [3] Medical Segment - The medical segment's revenue for Q1-Q3 2025 was 3.83 billion yuan, with significant growth in surgical consumables (185.3% increase), high-end dressings (26.2% increase), and health personal care products (24.6% increase) [4] - International sales channels contributed 2.18 billion yuan, marking an 81.7% year-on-year growth, with a notable increase in Southeast Asia and the Middle East [4] Consumer Segment - The consumer segment's revenue reached 4.01 billion yuan in Q1-Q3 2025, with the fastest growth seen in sanitary napkins, which generated 760 million yuan, a 63.9% increase [4] - E-commerce channels showed robust growth, achieving 2.46 billion yuan in revenue, a 23.5% increase, with significant contributions from interest e-commerce platforms [4] Financial Forecast - The company is projected to achieve revenues of 11.511 billion yuan in 2025, with a net profit of 995 million yuan, reflecting a growth rate of 28% and 43% respectively [6][7] - The estimated P/E ratios for the next few years are 23.93 for 2025, 20.35 for 2026, and 17.49 for 2027, indicating a favorable valuation trend [6][7]

Core Viewpoint - The stock of Steady Medical has experienced fluctuations, with a current price of 40.09 CNY per share and a market capitalization of 23.346 billion CNY, reflecting a year-to-date decline of 3.12% [1] Company Overview - Steady Medical, established on August 24, 2000, and listed on September 17, 2020, is located in Longhua District, Shenzhen, Guangdong Province. The company specializes in the research, production, and sales of cotton products [1] - The main revenue sources include consumer products such as wet and dry cotton towels (19.87%), medical consumables like surgical room products (18.15%), and traditional wound care products (13.88%) [1] Financial Performance - For the period from January to September 2025, Steady Medical reported a revenue of 7.897 billion CNY, marking a year-on-year growth of 30.10%. The net profit attributable to shareholders was 732 million CNY, reflecting a 32.36% increase compared to the previous year [2] - Since its A-share listing, the company has distributed a total of 2.875 billion CNY in dividends, with 1.729 billion CNY paid out in the last three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 15.06% to 32,100, with an average of 18,048 shares held per shareholder, up by 186.92% [2] - The top shareholders include Huabao Zhongzheng Medical ETF, holding 6.5935 million shares, and Hong Kong Central Clearing Limited, holding 4.8997 million shares, with notable changes in their holdings compared to the previous period [3]

Investment Rating - The investment rating for the company is "Accumulate" [1] Core Views - The company has demonstrated strong performance in Q3 2025, with total revenue of 7.9 billion yuan, representing a year-on-year increase of 30.1%, and a net profit attributable to shareholders of 730 million yuan, up 32.4% year-on-year [7] - The consumer segment, particularly the sanitary napkin category and e-commerce channels, has driven growth, with revenue from consumer products reaching 4.01 billion yuan, a year-on-year increase of 19.1% [7] - The medical segment has also shown robust growth, with medical consumables revenue of 3.83 billion yuan, up 44.4% year-on-year [7] - The overall gross margin has remained stable, with a slight increase to approximately 48.3% in Q1-Q3 2025, benefiting from a higher proportion of high-margin products in the consumer segment [7] - The company maintains a positive outlook for net profit growth, forecasting net profits of 1.045 billion yuan, 1.237 billion yuan, and 1.494 billion yuan for 2025, 2026, and 2027 respectively [7] Financial Summary - Total revenue for 2023 is projected at 8.185 billion yuan, with a year-on-year decrease of 27.89%, followed by a recovery in 2024 with an expected increase of 9.69% [1] - The net profit attributable to shareholders for 2023 is estimated at 580.4 million yuan, down 64.84% year-on-year, with a forecasted recovery to 695.38 million yuan in 2024, representing a 19.81% increase [1] - The earnings per share (EPS) for 2023 is projected at 1.00 yuan, with a forecasted increase to 1.19 yuan in 2024 [1] - The price-to-earnings (P/E) ratio is expected to decrease from 41.44 in 2023 to 34.59 in 2024, indicating improved valuation as earnings recover [1]

Core Viewpoint - The stock of Steady Medical has shown a positive trend recently, with a notable increase in trading volume and a significant rise in stock price over the past few weeks, indicating investor interest and confidence in the company's performance [1][2]. Company Overview - Steady Medical, established on August 24, 2000, and listed on September 17, 2020, is located in Longhua District, Shenzhen, Guangdong Province. The company specializes in the research, production, and sales of cotton products [1]. - The main revenue sources for Steady Medical include consumer products such as wet and dry cotton towels (19.87%), medical consumables like surgical room products (18.15%), and traditional wound care products (13.88%) [1]. Financial Performance - For the period from January to September 2025, Steady Medical reported a revenue of 7.897 billion yuan, reflecting a year-on-year growth of 30.10%. The net profit attributable to shareholders was 732 million yuan, marking a 32.36% increase compared to the previous year [2]. - Since its A-share listing, Steady Medical has distributed a total of 2.875 billion yuan in dividends, with 1.729 billion yuan paid out in the last three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Steady Medical reached 32,100, an increase of 15.06% from the previous period. The average number of circulating shares per person rose to 18,048, up by 186.92% [2]. - The top shareholders include Huabao Zhongzheng Medical ETF, holding 6.5935 million shares, and Hong Kong Central Clearing Limited, with 4.8997 million shares, showing changes in their holdings compared to the previous period [3].

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Insights - The company reported strong growth in the third quarter of 2025, with total revenue reaching 7.9 billion yuan, a year-on-year increase of 30.1%, and net profit attributable to the parent company at 732 million yuan, up 32.4% year-on-year [7] - The consumer goods segment continued to show high growth, with revenue of 4.01 billion yuan in the first three quarters, a 19.1% increase year-on-year, and a significant recovery in growth rate in the third quarter compared to the second quarter [7] - The medical business also demonstrated strong performance, with revenue of 3.83 billion yuan in the first three quarters, a 44.4% increase year-on-year, driven by both organic growth and the acquisition of GRI [7] - The company's profitability remained stable, with a gross margin of 48.3% and a net profit margin of 9.3% in the first three quarters [7] Financial Data and Profit Forecast - Total revenue forecast for 2025 is 10.779 billion yuan, with a year-on-year growth rate of 20.1% [6] - Net profit attributable to the parent company is expected to reach 1.026 billion yuan in 2025, reflecting a significant year-on-year growth of 47.6% [6] - Earnings per share are projected to be 1.76 yuan in 2025, with a price-to-earnings ratio of 23 [6]